Trial Profile
A Phase III, Randomized, Multicenter, Subject and Sponsor-blinded, Placebo Controlled Study to Compare the Efficacy and Safety of "Anagrelide Retard" Versus Placebo in "at Risk" Subjects With Essential Thrombocythaemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Anagrelide (Primary)
- Indications Embolism and thrombosis; Essential thrombocythaemia
- Focus Therapeutic Use
- Acronyms ARETA
- Sponsors AOP Orphan Pharmaceuticals AG
- 06 Dec 2016 Primary endpoint (Time to 1st clinically significant ET related event) has been met according to the results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 06 Dec 2016 Final results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 25 May 2016 Status changed from active, no longer recruiting to completed.